Elekta (OTCMKTS:EKTAY) Stock Price Down 7.3% – Here’s What Happened

Shares of Elekta AB (OTCMKTS:EKTAY – Get Free Report) traded down 7.3% on Wednesday . The stock traded as low as $4.9050 and last traded at $4.9050. Approximately 1,548 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 2,709 shares. The stock had previously closed at $5.29.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut shares of Elekta from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 2nd. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Elekta alerts:

View Our Latest Research Report on EKTAY

Elekta Stock Performance

The firm has a market cap of $1.81 billion, a PE ratio of -30.69 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.87 and a quick ratio of 0.68. The stock has a 50-day moving average price of $5.59 and a 200 day moving average price of $5.96.

Elekta (OTCMKTS:EKTAY – Get Free Report) last released its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The firm had revenue of $521.00 million for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. Research analysts forecast that Elekta AB will post 0.43 earnings per share for the current year.

About Elekta

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Read More

• Five stocks we like better than Elekta
• Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
• CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
• Why ASML’s AI Monopoly Is Still Getting Stronger
• Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.